Showing results (231-240 of 286) with videos related to

Sort By:
Pageof 29
Chest|July 10, 2025
A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung DiseaseRyo Hara, Satoshi Watanabe, Yuya Murase, et al.
Journal of Biomedical Science|July 11, 2024
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damageHiroshi Kotani, Hiroko Oshima, Justin C Boucher, et al.
Urologia Internationalis|March 13, 2010
Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between Japanese and Caucasian menTaku Misumi, Yoshiaki Yamamoto, Tomoyuki Murakami, et al.
Experimental Hematology & Oncology|September 28, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancersHiroshi Kotani, Tomoyoshi Yamano, Justin C Boucher, et al.
Molecular Cancer Therapeutics|May 10, 2011
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptorHirokazu Ogino, Masaki Hanibuchi, Soji Kakiuchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutationsHiromichi Ebi, Isao Oze, Takayuki Nakagawa, et al.
BMC Pulmonary Medicine|September 1, 2023
Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database studyTakashi Kobayashi, Yoshikazu Nishino, Tomoya Takiguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2025
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational studyYuichi Tambo, Takashi Sone, Koichi Nishi, et al.
Oncology Letters|August 7, 2012
A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancerHideki Tomimoto, Masaki Hanibuchi, Fumitaka Ogushi, et al.
Clinical Genitourinary Cancer|September 13, 2024
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score MatchingKeita Kobayashi, Hiroaki Matsumoto, Shigeru Sakano, et al.
Pageof 29